Clinical Trials on Bloom Syndrome

Total 116254 results

Samsung Medical Center

Unknown

Platelet Response During the Second Cycle of Decitabine Can Predict Response and Survival for Myelodysplastic Syndrome

Myelodysplastic Syndrome

Korea, Republic of
Cttq

Unknown

A Phase Ⅳ Study of Decitabine in Myelodysplastic Syndrome (DREAM)

Myelodysplastic Syndrome

China
Northwestern University
Robert H. Lurie Cancer Center

Terminated

Phase I/II Trial of Sodium Stibogluconate in Myelodysplastic Syndrome

Myelodysplastic Syndromes

United States
Fondazione Italiana Sindromi Mielodisplastiche-ETS

Withdrawn

Study of Clofarabine in Combination With Low Dose Cytarabine to Treat Myelodysplastic Syndromes (CLO2009AISSM05)

Myelodysplastic Syndromes

Italy
H. Lee Moffitt Cancer Center and Research Institute
Genentech, Inc.

Completed

Erlotinib Study for Myelodysplastic Syndrome (MDS)

Myelodysplastic Syndrome

United States
Gemin X

Completed

Safety and Efficacy of Obatoclax Mesylate (GX15-070MS)for the Treatment of Myelodysplastic Syndromes (MDS)

Myelodysplastic Syndromes

Canada, United States
Celgene Corporation

Completed

Efficacy and Safety Study of CC-5013 Monotherapy in Subjects With Myelodysplastic Syndromes

Myelodysplastic Syndromes

United States, Denmark, Australia, Belgium, Czech Republic, France, Germany, Greece, Italy, Netherlands, Russian Federation, Spain, Sweden, Switzerland, United Kingdom
Duke University
Eisai Inc.; Cephalon

Completed

Cephalon Decitabine, Arsenic Trioxide and Ascorbic Acid for Myelodysplastic Syndrome

Myelodysplastic Syndrome

United States
Tel-Aviv Sourasky Medical Center

Unknown

Safety And Efficacy Of Azacitidine, and Lenalidomide In Higher Risk Myelodysplastic Syndrome (ViLen 001)

Myelodysplastic Syndrome

Israel
M.D. Anderson Cancer Center

Completed

Treatment of Myelodysplastic Syndrome (MDS) With Cytokine-Immunotherapy for Low-Risk MDS

Myelodysplastic Syndrome

United States
Veeda Oncology
Cephalon

Terminated

A Phase II Trial of Trisenox Plus Thalomid as Treatment in Patients With Myelodysplastic Syndrome

Myelodysplastic Syndrome

United States
Centre Hospitalier Universitaire de Nice

Terminated

A Trial of Bevacizumab in Myelodysplastic Syndromes (Int-1, Int-2 and High Risk According to International Prognostic Scoring System (IPSS)) With Excess of Marrow Blasts

Myelodysplastic Syndromes

France
Fondazione Amelia Scorza Onlus

Unknown

Collection of Biological Data With Potential Prognostic Relevance in Patients With MYELODYSPLASTIC SYNDROMES (O-MDS-Protocol)

Myelodysplastic Syndrome

Italy
Shandong University
National Natural Science Foundation of China

Unknown

Safety and Efficacy Study of Umbilical Cord/Placenta-Derived Mesenchymal Stem Cells to Treat Myelodysplastic Syndromes

Myelodysplastic Syndromes

China
medac GmbH

Completed

Treosulfan Based Conditioning Myelodysplastic Syndrome (MDS)

Myelodysplastic Syndrome

Finland
Fundacion para el Estudio de la Hematologia y Hemoterapia...

Terminated

Prospective, Multicenter, Open Label and Single-arm Study of Darbepoetin Alfa for Anemia in Myelodisplastic Syndrome Patients.

Myelodysplastic Syndrome

Spain
Telik

Completed

Study of TLK199 HCl Liposomes for Injection in Myelodysplastic Syndrome

Myelodysplastic Syndromes

United States
National Institutes of Health Clinical Center (CC)

Completed

A Randomized Trial of Antithymocyte Globulin Versus Cyclosporine to Treat the Cytopenia of Myelodysplastic Syndrome

Myelodysplastic Syndromes | Hematologic Diseases

United States
Groupe Francophone des Myelodysplasies

Unknown

Darbepoetin Alpha in Myelodysplastic Syndromes (MDS)

Myelodysplastic Syndromes

France
Groupe Francophone des Myelodysplasies

Completed

Thalidomide at Low Dose for the Treatment of Patient With Myelodysplastic Syndromes - THAL-SMD-200

Myelodysplastic Syndromes

France
Groupe Francophone des Myelodysplasies

Unknown

Bortezomib and Low Dose Cytarabine in the Treatment of High-Risk Myelodysplastic Syndromes

Myelodysplastic Syndromes

France
Celgene Corporation

Completed

A Study to Access the Safety/Efficacy of Thalidomide in the Treatment of Anemia in Patients With Myelodysplastic Syndromes

Myelodysplastic Syndromes

United States
Minovia Therapeutics Ltd.

Recruiting

A Study to Evaluate the MNV-201 in Patients With Low Risk MDS

Myelodysplastic Syndromes

Israel
Wuhan Union Hospital, China

Not yet recruiting

A Novel Conditioning Regimen for Myelodysplastic Syndrome With Moderate High IPSS-M Score

Myelodysplastic Syndromes
Assistance Publique - Hôpitaux de Paris

Not yet recruiting

JAK Inhibitor in Acquired Hemophagocytic synDrome in the Intensive Care Unit (JAKAHDI)

Hemophagocytic Syndromes
Otsuka Beijing Research Institute

Recruiting

PK/Efficacy Bridging Study of ASTX727 in Chinese Subjects With Myelodysplastic Syndromes

Myelodysplastic Syndromes

China
Bristol-Myers Squibb

Recruiting

A Study to Assess Luspatercept in Lower-risk Myelodysplastic Syndrome Participants (MAXILUS)

Myelodysplastic Syndromes

Spain, United States, France, Italy, Belgium, Germany, Poland, Czechia, Puerto Rico
Peking Union Medical College Hospital

Not yet recruiting

Roxadustat Combined With Luspatercept Versus Luspatercept Monotherapy in the Treatment of Refractory MDS-RS

Myelodysplastic Syndromes

China
University Hospital, Grenoble

Recruiting

Flow Cytometric Analysis of Peripheral Blood Neutrophil Myeloperoxidase Expression for Ruling Out Myelodysplastic Syndromes: Protocol for a Diagnostic Accuracy Study (MPO-MDS-Valid)

Myelodysplastic Syndromes

France
Novartis Pharmaceuticals

Recruiting

Study of Efficacy and Safety of Eltrombopag in Lower-risk MDS Patients With Platelet Transfusion Dependence

Myelodysplastic Syndromes

Japan
H. Lee Moffitt Cancer Center and Research Institute
Novartis Pharmaceuticals

Recruiting

Canakinumab With Darbepoetin Alfa in PTs With Lower-Risk MDS Who Have Failed ESA

Myelodysplastic Syndromes

United States
Novartis Pharmaceuticals

Terminated

Phase Ib Study of Select Drug Combinations in Patients With Lower Risk MDS

Myelodysplastic Syndromes

United States, Spain, Italy, Singapore, Korea, Republic of, Israel, Australia
Bristol-Myers Squibb

Active, not recruiting

A Study to Compare the Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in Participants With International Prognostic Scoring System Revised (IPSS-R) Low- or Intermediate-risk Myelodysplastic Syndrome (MDS)

Myelodysplastic Syndromes

Argentina, Canada, France, Germany, Italy, Korea, Republic of, Poland, United States, Australia, China, Czechia, Denmark, Greece, Hong Kong, Japan, Spain, Sweden
University Hospital, Grenoble

Active, not recruiting

Development and Prospective Validation of a Standardized Flow Cytometric Assay of Peripheral Blood Neutrophil Myeloperoxidase Expression for Ruling Out Myelodysplastic Syndromes. (MPO-MDS-Develp)

Myelodysplastic Syndromes

France
Asan Medical Center

Active, not recruiting

CyFluATG in Lower Risk MDS

Myelodysplastic Syndromes

Korea, Republic of
Asan Medical Center

Completed

Hematopoietic Cell Transplantation With Post-transplantation Cyclophosphamide in MDS

Myelodysplastic Syndromes

Korea, Republic of
Thomas Jefferson University

Withdrawn

Physical Activity in Transfusion Dependent Patients With Myelodysplastic Syndrome

Myelodysplastic Syndromes

United States
Sidney Kimmel Comprehensive Cancer Center at Johns...
National Cancer Institute (NCI); Alliance for Cancer Gene Therapy

Terminated

Vaccine Therapy in Treating Patients With Myelodysplastic Syndromes

Myelodysplastic Syndromes

United States
Janssen Research & Development, LLC

Completed

Study to Separately Evaluate the Activity of Talacotuzumab (JNJ-56022473) or Daratumumab in Transfusion-Dependent Participants With Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) Who Are Relapsed or Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment

Myelodysplastic Syndromes

United States, Belgium, Italy, Spain, Netherlands, Russian Federation
SymBio Pharmaceuticals

Completed

Safety and Pharmacokinetics Study of SyB L-1101 in Patients With Recurrent/Relapsed or Refractory Myelodysplastic Syndrome (MDS)

Myelodysplastic Syndrome

Japan
SymBio Pharmaceuticals

Completed

Safety and Pharmacokinetics Study of SyB C-1101 in Patients With Recurrent/Relapsed or Refractory Myelodysplastic Syndrome (MDS)

Myelodysplastic Syndrome

Japan
SymBio Pharmaceuticals

Withdrawn

Combination Therapy of SyB C-1101 and Azacytidine in Patients With Myelodysplastic Syndrome

Myelodysplastic Syndrome

Japan
The University of Hong Kong

Active, not recruiting

Enhanced Palliative Care in MDS and AML

Myelodysplastic Syndromes

Hong Kong
Groupe Francophone des Myelodysplasies

Completed

CPX-351 in Higher Risk Myelodysplastic Syndromes

Myelodysplastic Syndromes

France
Helsinn Healthcare SA

Terminated

A Safety and Efficacy Study of Pracinostat and Azacitidine in Patients With High Risk Myelodysplastic Syndromes

Myelodysplastic Syndromes

United States
Acceleron Pharma Inc. (a wholly owned subsidiary...

Completed

ACE-536 Extension Study - Myelodysplastic Syndromes

Myelodysplastic Syndromes

Germany
Grupo Cooperativo de Estudio y Tratamiento de las...
Celgene Corporation; Germans Trias i Pujol Hospital; Hospital Son Llatzer

Unknown

Treatment of High Risk Myelodysplastic Syndromes (MDS) Not Candidates for Allogeneic Transplantation of Hematopoietic Progenitors (ALO-HSCT)

Myelodysplastic Syndromes

Spain
Samsung Medical Center

Completed

Clinical Relevance of DNMT and HDAC Gene SNP on the Response to Decitabine Therapy for Myelodysplastic Syndrome

Myelodysplastic Syndrome

Korea, Republic of
University Hospital, Toulouse
National Cancer Institute, France

Completed

PREDICTive FactOR of Overall Survival Among Geriatric Assessment Tools and Disease Related Factors in Elderly Patients With High Risk Myelodysplastic Syndromes. (PREDICTOR)

Myelodysplastic Syndromes

France, Monaco
Hoffmann-La Roche

Completed

A Study of Epoetin Beta Treatment in Anemic Participants With Myelodysplastic Syndrome (MDS)

Myelodysplastic Syndromes

Thailand

3

Subscribe